Burosumab

Sustained burosumab therapy for more than 3 years for children with X-linked hypophosphatemia resulted in clinically meaningful improvements across several clinical outcomes and demonstrated an acceptable benefit-risk profile, data show.

Patients with both X-linked hypophosphatemia and tumor-induced osteomalacia can benefit from phosphorus replacement therapy, according to two presentations at the United Rheumatology Spring Virtual conference.

Treatment with the monoclonal antibody burosumab led to normalized serum phosphorus levels and improvements in rickets severity and lower-limb deformity among young children with X-linked hypophosphatemia, according to a speaker.

In June, the FDA approved burosumab for a second rare bone disease, expanded the indication for an interoperable insulin pump, cleared an integrated continuous glucose monitor, and approved a biosimilar and a new faster-acting insulin. 

The FDA approved burosumab-twza injection to treat patients aged 2 years and older with tumor-induced osteomalacia, according to an agency press release.

A small cohort of adults with tumor-induced osteomalacia experienced improvements in phosphate and skeletal metabolism, physical functioning and quality of life after 144 weeks of treatment with burosumab therapy, study data show.